INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

May 31, 2010

Conditions
Cardiovascular Disease
Interventions
DRUG

eptifibatide

Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure

DRUG

placebo

Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure

Trial Locations (1)

20144

Mediolanum Cardio Research, Milan

All Listed Sponsors
lead

Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

OTHER

NCT00638976 - INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial | Biotech Hunter | Biotech Hunter